

C-Path and EATRIS Join Forces with New Collaboration Agreement



AMSTERDAM and **TUCSON**, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastructure for Translational Medicine) are pleased to announce the signing of a collaboration agreement aimed at fostering actionable scientific and educational cooperation. This agreement marks a significant milestone in the pursuit of patient-centric innovation and the advancement of translational medicine research.

Under the terms of the collaboration agreement, C-Path and EATRIS have outlined several key objectives that will drive their joint efforts. These include the facilitation of data sharing, and the development of data science and regulatory science best practices to improve translational medicine processes. Both organisations will collaborate on scientific and professional activities, jointly organise workshops and courses and provide opportunities for scientists to collaborate on specific projects.

Cecile Ollivier, C-Path Managing Director for Europe, emphasized the importance of addressing the pressing challenges in medicines development early in the process, “When translational science and regulatory science work together it can lead to drug development trials that can quickly yield more effective, affordable and safe medical products for patients. Together, C-Path and EATRIS can overcome technical and operational gaps across the drug development lifecycle.”

Anton Ussi, EATRIS Operations and Finance Director, expressed his enthusiasm about the agreement, “Having the opportunity to work closely with C-Path is very exciting; our shared passion for people-centric science is an ideal starting point. We have so much to do in the battle for better patient outcomes and are looking forward to getting started together.”

The collaboration between C-Path and EATRIS brings together their collective knowledge, resources and dedication to driving scientific advancements in translational medicine. By combining their expertise, the two organisations aim to accelerate the development of innovative treatments and improve patient outcomes.



About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the [FDA's Critical Path Initiative](#). **C-Path's mission is to lead collaborations that advance better treatments for people worldwide.** Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org or email info@c-path.org.



European infrastructure
for translational medicine

About EATRIS

EATRIS is the European Infrastructure for Translational Medicine. It's a non-profit organisation that brings together resources and services for research communities to translate scientific discoveries into benefits for patients. Users are given access to a vast array of expertise and facilities from over 145 top-tier academic centres across Europe. EATRIS focuses on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics, and overcoming barriers to health innovation. Find out more about EATRIS here: eatris.eu, [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

Contact:

Kissy Black
C-Path
615.310.1894
kblack@c-path.org